Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Lin, Yulia ^b   Stanworth, Simon ^a   Birchall, Janet ^c   Doree, Carolyn ^c   Hyde, Chris ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Blood loss, surgical *prevention control ; Factor VIIa adverse effects; *therapeutic use ; Hemorrhage *drug therapy ; Hemostatics adverse effects; *therapeutic use ; Humans; Randomized controlled trials as topic; Recombinant proteins therapeutic use

Indexed keywords

ALLOANTIBODY; APROTININ; HEPARIN; PLACEBO; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BURN; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG SAFETY; EMBASE; HEMOPHILIA; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; MORTALITY; OPERATION DURATION; PARTIAL HEPATECTOMY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOSIS; TRANSFUSION; TREATMENT OUTCOME;

EID: 77950224893     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Boffard 2005a {published data only} Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al.Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized placebo-controlled double blind clinical trials. Journal of Trauma 2005;59:8-18.
2. Boffard 2005b {published data only} Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint, et al.Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized placebo-controlled double blind clinical trials. Journal of Trauma 2005;59:8-18.
3. Bosch 2004 {published data only} Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonzalez Abraldes J, et al.Recombinant factor VIIa for upper gastrointestinal bleeding patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004;127:1123-30.
4. Bosch 2008 {published data only} Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, et al.Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008;47:1604-14.
5. Chuansumrit 2005 {published data only} Chuansumrit A, Wangruangsatid S, Lektrakul Y, Chua MN, Zeta Capeding MR, Bech OM, et al.Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagulation & Fibrinolysis 2005;16(8):549-55.
6. Diprose 2005 {published data only} * Diprose P, Herbertson M, O'Shaughnessy D, Gill R. A pilot double blind randomized placebo-controlled trial of the use of recombinant factor VIIa (rf VIIa) in high transfusion risk cardiac surgery. European Journal of Anaesthesiology 2005;21(Suppl. 33):2-36.
7. Herbertson M. Recombinant activated factor VII in cardiac surgery. Blood Coagulation & Fibrinolysis 2004;15(Suppl 1):S31-2.
8. Ekert 2006 {published data only} Ekert H, Brizard C, Eyers R, Cochrane A, Henning R. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagulation & Fibrinolysis 2006;17(5):389-95.
9. Essam 2007 {published data only} Essam MA. Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery. Internet Journal of Anesthesiology 2007;13(1):10.
10. Friederich 2003 {published data only} Friederich PW, Geerdink MGF, Keller TT, Messelink EJ, Henny Ch P, Levi M. Novel applications of recombinant factor VIIa: the effect of the administration of recombinant activated factor VII on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Infusionstherapie und Transfusionsmedizin 2001;28(2):112-3.
11. Friederich PW, Geerdink MGF, Spataro M, Messelink EJ, Henny Ch P, Buller HR, et al.The effect of the administration of recombinant activated factor VII on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coagulation & Fibrinolysis 2000;11(suppl 1):S129-32.
12. * Friederich PW, Keller T, Buller HR, Levi M. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003;361(9353):201-5.
13. Jeffers 2002 {published data only} Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002;123:118-26.
14. Johansson 2007 {published data only} Johansson PI, Eriksen K, Nielsen SL, Rojkjaer R, Alsbjorn B. Recombinant FVIIa decreases perioperative blood transfusion requirement in burn patients undergoing excision and skin grafting - results of a single centre pilot study. Burns 2007;33:435-40.
15. Lodge 2005a {published data only} * Lodge JP, Jonas S, Oussoultzoglou E, Malago M, Jayr C, Cherqui D, et al.Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005;102:269.
16. Lodge JPA. Hemostasis in liver resection surgery. Seminars in Hematology 2004;41(suppl 1):70-5.
17. Lodge 2005b {published data only} * Lodge JP, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S, et al.Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transplantation 2005;11(8):973-9.
18. Lodge JPA. Hemostasis in liver resection surgery. Seminars in Hematology 2004;41(suppl 1):70-5.
19. Ma 2006 {published data only} Ma B, Wang ZN, Zhang BR, Xu ZY, Yang LX, Chen KB, et al.Effect of recombinant activated factor VIIa on early recovery of patients undergoing cardiac valve replacement under cardiopulmonary bypass: a randomized double-blind placebo-controlled trial. Academic Journal of Second Military Medical University 2006;27:1110-3.
20. Mayer 2005a {published data only} Mayer SA. Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy. Intensive Care Medicine 2002;28:S235-40.
21. * Mayer SA, Nikolai MD, Brun C, Begtrup K, Broderick J, Davis S, et al.Recombinant activated factor VII for acute intracerebral hemorrhage. New England Journal of Medicine 2005;352:777-85.
22. Pickard JD, Kirkpatrick PJ, Melsen T, Andreasen RB, Gelling L, Fryer T, et al.Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagulation & Fibrinolysis 2000;11(suppl 1):S117-20.
23. Mayer 2005b {published data only} Mayer SA. Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy. Intensive Care Medicine 2002;28:S235-40.
24. * Mayer SA, Brun NC, Broderick J, Davis S, Diringer MN, Skolnick BE, et al.Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005;36:74-9.
25. Pickard JD, Kirkpatrick PJ, Melsen T, Andreasen RB, Gelling L, Fryer T, et al.Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagulation & Fibrinolysis 2000;11(suppl 1):S117-20.
26. Mayer 2006 {published data only} Mayer SA, Brun NC, Broderick J, Davis SM, Diringer MN, Skolnick BE, et al.Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocritical Care 2006;4:206-14.
27. Mayer 2008 {published data only} Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al.Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. New England Journal of Medicine 2008;358(20):2127-37.
28. Narayan 2008 {published data only} Narayan RK, Maas AI, Marshall LF, Servadei F, Skolnick BE, Tillinger MN, rFVIIa Traumatic ICH Study Group. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. Neurosurgery 2008;62:776-86. [: Clinicaltrials.gov Identifier: NCT00123591]
29. Pihusch 2005 {published data only} Bacigalupo A. Haemopoietic stem cell transplants: the impact of haemorrhagic complications. Blood Reviews 2003;17:S6-10.
30. * Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L, et al.Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. Journal of Thrombosis & Haemostasis 2005;3(9):1935-44.
31. Planinsic 2002 {published data only} Planinsic RM, Testa G, Grande L, Candela A, van der Meer J, Porte RJ, et al.Safety and efficacy of single bolus dose of recombinant factor VIIa in patients undergoing orthotopic liver transplantation: a randomized multi-centre study. Hepatology 2002;11(8):896-900.
32. Pugliese 2007 {published data only} Pugliese F, Ruberto F, Summonti D, Perrella S, Cappannoli A, Tosi A, et al.Activated recombinant factor VII in orthotopic liver transplantation. Transplantation Proceedings 2007;39:1883-5.
33. Raobaikady 2005 {published data only} Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis and acetabulum: a double-blind randomized, placebo-controlled trial. British Journal of Anaesthesia 2005;94:586-91.
34. Sachs 2007 {published data only} Sachs B, Delacy D, Green J, Graham RS, Ramsay J, Kreisler N, et al.Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, doseescalation trial. Spine 2007;32:2285-93.
35. Shao 2006 {published data only} Shao YF, Yang JM, Chau GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E, et al.Safety and hemostatic effect of recombinant activated factor VIIa in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. American Journal of Surgery 2006;191:245-9.
36. Ashrani 2006 {published data only} Ashrani AA, Gabriel DA, Gajewski JL, Jacobs DRJ, Weisdorf DJ, Key NS. Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy. Bone Marrow Transplantation 2006;38(12):825-8.
37. Bijsterveld 2002 {published data only} Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, et al.Ability of recombinant factor VIIa to reverses the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002;106(20):2550-4.
38. Bijsterveld 2004 {published data only} Bijsterveld NR, Vink R, van Arken BE, Fennema H, Peters RJG, Meijers JCM, et al.Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. British Journal of Haematology 2004;124:653-8.
39. Bysted 2007 {published data only} Bysted BV, Scharling B, Møller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 2007;13(5):527-32.
40. Davis 2004 {published data only} Davis S, Mayer S, Brun N, Broderick J, Diringer MN, Steiner T. Safety of activated recombinant factor VII in acute intracerebral hemorrhage: results of two multi-center placebo-controlled trials. Internal Medicine Journal 2004;34:1-2.
41. Diringer 2007 {published data only} Diringer MN, Ferran JM, Broderick JP, Davis S, Mayer SA, Steiner T, et al.Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage. Cerebrovascular Diseases (Basel Switzerland) 2007;23(2-3):219-25.
42. Fridberg 2005 {published data only} Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagulation and Fibrinolysis 2005;16:259-66.
43. Jilma 2002 {published data only} Jilma B, Marsil C, Mayr F, Graninger MT, Taylor FB, Ribel MC, et al.Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clinical Pharmacology and Therapeutics 2002;72:403-10.
44. Kolban 2005 {published data only} Kolban M, Balachowska KI, Chmielnicki M. The use of recombinant coagulation factor VIIa in patients undergoing surgical correction of scoliosis with the C-D method. Ortopedia Traumatologia Rehabilitacja 2005;7(3):285-9.
45. Macieji 2004 {published data only} Macieji K, Ina BK, Slawomir Z, Lukasz K. Use of small doses of recombinant factor VIIa during scoliosis surgery. Journal of Bone and Joint Surgery (Proceedings) 2004;86 B.C.(Suppl 1):94-9a.
46. Perez 2007 {published data only} Perez AF, Serra C, Macia J, Mayol L. rFVII for pediatric acute intracranial hemorrhage (15). Stroke 2007;38(7):E63-4.
47. Plaat 2007 {published data only} Plaat F. Recombinant factor VIIa should be used in massive obstetric haemorrhage. International Journal of Obstetric Anesthesia 2007;16(4):354-7.
48. Pugh 2007 {published data only} Pugh R, Wenstone R. Predicting response to recombinant factor VIIa in non-haemophilia patients with severe haemorrhage (1). British Journal of Anaesthesia 2007;98(5):690.
49. Van De Velde 2007 {published data only} Van De Velde M. Recombinant factor VIIa should be used in massive obstetric haemorrhage. International Journal of Obstetric Anesthesia 2007;16(4):357-9.
50. Vink 2004 {published data only} Vink R, Bijsterveld NR, Van Aken BE, Fennema H, Peters RJG, Joost CM, et al.Recombinant factor VIIa reverses the anticoagulant effect of the long-standing anticoagulant idraparinux in healthy volunteers. Blood 2004;102(11):812a.
51. Woltz 2004 {published data only} Woltz M, Levi M, Sarich LC, Bostram SL, Eriksson UG, Eriksson-Lepkoska M, et al.Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thrombosis and Haemostasis 2004;91(6):1090-6.
52. Arai 2005 {published and unpublished data} Arai M. Factor VIIa: Safety of Eptacog Alfa (activated) (genetical recombination) on adverse events and serious adverse events in patients with acute intracerebral haemorrhage. ClinicalTrials.gov 2005. [: ClinicalTrials.gov Identifier: NCT00266006; : Novo Nordisk Clinical Trial ID: F7ICH-1602]
53. Flaherty 2008 {published data only} Flaherty ML, Jauch EC. The Spot sign for predicting and treating intracerebral hemorrhage growth study. Clinicaltrials.gov 2008. [: Clinicaltrials.gov Identifier: NCT00810888]
54. Gajewski 2005 {unpublished data only} Gajewski JL, Vogelsang G, Key N, Goodnough L. A multi-center, randomized, double-blind, parallel groups, placebo-controlled trial on efficacy and safety of activated recombinant factor VII (rFVIIa/NovoSeven) in the treatment of bleeding in patients following hematopoietic stem cell transplantation (HSCT). Novo Nordisk Clinical Trial ID: F7SCT-1485 2005.
55. Gaspar-Blaudschun 2004 {published and unpublished data} Gaspar-Blaudschun B. A multicentre-randomised, double-blind, placebo-controlled, dose escalation trial on safety and efficacy of activated recombinant factor VII (rFVIIa/NovoSeven® ) in the treatment of post-operative bleeding in patients following cardiac surgery requiring cardiopulmonary bypass. Clinicaltrials.gov 2004. [: Clinicaltrials.gov Identifier: NCT00154427; : Novo Nordisk Clinical Trial ID: F7CARD-1610]
56. Sellke F, Gill R, Vulysteke A, Olsen PS, Heymann CV, Mythen M, et al.The safety and efficacy of recombinant activated factor VII for the treatment of bleeding following cardiac surgery: a multinational randomized, placebo-controlled trial. Circulation 2008;118:1259.
57. Gris 2006 {published data only} Gris JC. rhuFVIIa in post-partum hemorrhage. ClinicalTrials.gov 2006. [: Clinicaltrials.gov Identifier: NCT00370877]
58. Imberti 2005 {published and unpublished data} Imberti R. Efficacy and safety of factor VIIa (Eptacog Alfa) on rebleeding after surgery for spontaneous supratentorial intracerebral hemorrhage. A randomized, controlled, open-label, investigator-blinded pilot study. ClinicalTrials.gov 2005. [: ClinicalTrials.gov Identifier: NCT00128050]
59. Iorio 2006 {published and unpublished data} Iorio A. Randomized, open, prospective, multicenter pilot study to evaluate the efficacy and safety of activated recombinant factor VII in acute intracerebral haemorrhage in patients treated with oral anticoagulants or antiplatelets agents. ClinicalTrials.gov 2006. [: ClinicalTrials.gov Identifier: NCT00222625]
60. Kelleher 2006 {published data only} Kelleher A. A multi-centre, randomised, double-blind, placebo-controlled, dose-escalation trial of safety and efficacy of activated recombinant factor VII (Rfv11a/NovoSeven) in the treatment of post-operative bleeding in patients following cardiac surgery requiring cardiopulmonary bypass. http://www2.rbht. nhs.uk/research/projects.
61. McCall 2005 {published and unpublished data} McCall P, Poustie S. "Salvage use" of recombinant activated factor VII after inadequate haemostatic response to conventional therapy in complex cardiac surgery - a randomised placebo-controlled trial. ClinicalTrials.gov 2005. [: ClinicalTrials.gov Identifier: NCT00214656]
62. Molter 2005 {published and unpublished data} Molter NC, Park MS, Frail EA. Effect of recombinant coagulation factor VIIa on peri-operative blood loss in patients undergoing major burn excision and grafting. ClinicalTrials.gov 2005. [: ClinicalTrials.gov Identifier: NCT00243243]
63. Ng 2006 {published and unpublished data} Ng C. Use of recombinant activated factor seven (FVII) in bleeding ECMO patients post cardiac surgery. Randomised prospective study. National Research Register 2005. [: N0012154243; ISRCTN98382551]
64. Tortella 2006 {unpublished data only} Tortella B. A multi-center randomized double-blind parallel group placebo controlled trial to evaluate the efficacy and safety of rFVIIa in the treatment of refractory bleeding in severely injured trauma patients. Clinicaltrials.gov 2006. [: Clinicaltrials.gov Identifier: NCT00184548; : Clinicaltrials.gov Identifier: NCT00323570]
65. Ahonen 2005 Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. British Journal of Anaesthesia 2005;94(5):592-5.
66. Birchall 2008 Birchall J, Stanworth SJ, Duffy MR, Doree CJ, Hyde C. Evidence for the use of recombinant factor VIIa in the prevention and treatment of bleeding in patients without hemophilia. Transfusion Medicine Reviews 2008;22:177-87.
67. Brun 2005 Brun NC, Skolnick B. Treatment with recombinant factor VIIa in patients with acute intracerebral haemorrhage by reducing hematoma growth. ClinicalTrials.gov 2005. [: Clinicaltrials.gov Identifier: NCT00127283]
68. Butenas 2002 Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood (Comment). Blood 2002;100(1):364-5.
69. Bysted 2007 Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia 2007;13:527-32.
70. Canadian Blood Services 2009 Canadian Blood Services. Correspondence 2009.
71. Davis 2006 Davis SM, Broderick J, Hennerici M, et al.Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006;66:1175-81.
72. Della Corte 2006 Della Corte F. Efficacy and safety of factor VIIa on rebleeding after surgery for spontaneous intracerebral hemorhage (ICH). Clinical Trials.gov 2006. [: Clinicaltrials.gov Identifier: NCT00128050]
73. Diringer 2008 Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, et al.Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 2008;39:850-6.
74. Erhardtsen 2002 Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Medicine 2002;28(Suppl 2):S248-55.
75. Fabricius 2006 Fabricius S. Use of NovoSeven in active variceal bleeding. ClinicalTrials.gov 2006. [: Clinicaltrials.gov Identifier: NCT00154492]
76. Franchini 2007a Franchini M, Veneri D, Lippi G. The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. Bone Marrow Transplantation 2007;39:729-35.
77. Franchini 2007b Franchini M, Manzato F, Salvagno GL, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagulation & Fibrinolysis 2007;18:589-93.
78. Franchini 2008a Franchini M, Franchi M, Bergamini V, Salvagno GL, Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Seminars in Thrombosis and Hemostasis 2008;34:104-12.
79. Franchini 2008b Franchini M, Montagnana M, Targher G, Zaffanello M, Lippi G. The use of recombinant factor VIIa in liver diseases. Blood Coagulation and Fibrinolysis 2008;19:341-8.
80. Goodnough 2004 Goodnough LT, Lublin DM, Zhang L. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004;44:1325-31.
81. Greisen 2003 Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagulation & Fibrinolysis 2003;14(1):117-20.
82. Hardy 2008 Hardy JF, Bélisle S, Van der Linden P. Efficacy and safety of recombinant activated factor VII to control bleeding in nonhemophiliac patients: a review of 17 randomized controlled trials. Annals of Thoracic Surgery 2008;86:1038-48.
83. Hay 2006 Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. British Journal of Haematology 2006;133:591-605.
84. Hedner 2002 Hedner U, Erhardtsen E. Potential role for rVIIa in transfusion medicine. Transfusion 2002;42(1):114-24.
85. Hendriks 2001 Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, et al.Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001;71(3):402-5.
86. Higgins 2008 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2008.
87. Hsia 2008 Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Annals of Surgery 2008;248:61-8.
88. Isbister 2008 Isbister J, Phillips L, Dunkley S, Jankelowitz G, McNeil J, Cameron P. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register. Internal Medicine Journal 2008;38:156-65.
89. Johansson 2008 Johansson PI. Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials. Vox Sanguinis 2008;95:1-7.
90. Key 2003a Key NS, Mast AE. Factor VIIa and tissue factor pathway inhibitor. In: Stowell C, Dzik W editor(s). Emerging Technologies in Transfusion Medicine. AABB Press, 2003.
91. Key 2003b Key NS. Recombinant FVIIa for intractable hemorrhage: more questions than answers. Transfusion 2003;43(12):1649-51.
92. Kruse 2005 Kruse P. Evaluation of safety of activated recombinant FVII as an add-on therapy in spinal surgery. Clinicaltrials.gov 2005. [: Clinicaltrials.gov Identifier: NCT00102037]
93. Lodge 2002 Lodge P, Jonas S, Jaeck D, Fridberg MJ. Recombinant factor VIIa (Novoseven) in partial hepatectomy: a randomized placebo-controlled, double-blinded clinical trial. Hepatology 2002;36:211A.
94. Lusher 1998 Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, et al.A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998;4(6):790-8.
95. Marti-Carvajal 2007 Martí-Carvajal AJ, Salanti G, Marti-Carvajal PI. Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD004887.pub2]
96. Martinowitz 2001 Martinowitz U, Holcomb JB, Pusateri AE, Stein M, Onaca N, Freidman M, et al.Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. Journal of Trauma 2001;50(4):721-9.
97. Martinowitz 2005 Martinowitz U, Michaelson M, on behalf on the Israeli Multidisciplinary rVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. Journal of Thrombosis and Haemostasis 2005;3(4):640.
98. Mathew 2006 Mathew P, Young G. Recombinant factor VIIa in paediatric bleeding disorders - a 2006 review. Haemophilia 2006;12:457-72.
99. Moltzan 2008 Moltzan CJ, Anderson DA, Callum J, Fremes S, Hume H, Mazer CD. The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework. Transfusion Medicine 2008;18:112-20.
100. O'Connell 2003 O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant factor VIIa in the management of uncontrolled hemorrhage. Transfusion 2003;43(12):1711-6.
101. O'Connell 2006 O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295(3):293-8.
102. Pape 2006 Pape H, Erhardtsen E, Meyer C, Leppäniemi A. Recombinant factor VIIa for life-threatening hemorrhage in trauma patients: review of the literature. European Journal of Trauma 2006;32:439- 48.
103. Patanwala 2008 Patanwala AE. Factor VIIa (recombinant) for acute traumatic hemorrhage. American Journal of Health-System Pharmacy 2008;65:1616-23.
104. Ranucci 2008 Ranucci M, Isgro G, Soro G, Conti D, De Toffol B. Efficacy and safety of recombinant activated factor VII in major surgical procedures. Archives of Surgery 2008;143:296-304.
105. RevMan 2008 The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008.
106. Roberts 2001 Roberts HR. Recombinant factor VIIa (NovoSeven) and the safety of treatment. Seminars in Haematology 2001;4(Suppl. 12):48-50.
107. Roberts 2004 Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004;104(13):3858-64.
108. Rubinger 1999 Rubinger M, Rivard GE, Teitel J, Walker I. Suggestions for the management of hemophiliacs and non-hemophiliacs with factor VIII inhibitors. AHCDC Clinical Practice Guidelines, 3rd edition 1999. [: Available at http://www.ahcdc.ca/FVIIIsuggestions.html]
109. Skolnick 2005 Skolnick B. Dose response to recombinant factor VIIa when administered for bleed. ClinicalTrials.gov. [: Clinicaltrials.gov Identifier: NCT00104455]
110. Squizzato 2007 Squizzato A, Ageno W. Recombinant activated factor VII as a general haemostatic agent: evidence-based efficacy and safety. Current Drug Safety 2007;2:155-61.
111. Tillinger 2005 Tillinger M. Evaluation of safety and preliminary efficacy of recombinant activated factor VII in subjects with brain contusions. ClinicalTrials.gov 2005. [: ClinicalTrials.gov Identifier: NCT00123591]
112. von Heymann 2008 von Heymann C, Jonas S, Spies C, Wernecke KD, Ziemer S, Janssen D, et al.Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Critical Care 2008;12:R14.
113. Warren 2007 Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, et al.Recombinant activated factor VII in cardiac surgery: a systematic review. Annals of Thoracic Surgery 2007;83:707-14.
114. Warren 2008 Warren OJ, Alcock EM, Choong AM, Leff DR, Van Herzeele I, Darzi AW, et al.Recombinant activated factor VII: a solution to refractory haemorrhage in vascular surgery?. European Journal of Vascular and Endovascular Surgery 2008;35:145-52.
115. You 2006 You H, Al-Shahi R. Haemostatic drug therapies for acute primary intracerebral haemorrahge. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD005951.pub2]
116. Zangrillo 2009 Zangrillo A, Mizzi A, Biondi-Zoccai G, Bignami E, Calabrò MG, Pappalardo F, et al.Recombinant activated factor VII in cardiac surgery: a meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia 2009;23:34-40.
117. Stanworth 2007 Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD005011.pub2]